脑肿瘤术后手术部位感染需去骨瓣患者的颅骨修补:瑞典15年多中心研究
该多中心观察性研究纳入2008至2022年瑞典四家神经外科中心因脑肿瘤术后手术部位感染行去骨瓣的260例患者,其中223例(86%)后续接受颅骨修补,全部使用合成植入物。颅骨修补后植入物取出率为21%,WHO 4级肿瘤和骨缺损>64.5 cm²与植入物取出风险增加相关(p<0.05),多数患者术后功能结局(mRS)不变(87%)。
要点
- 脑肿瘤术后SSI去骨瓣患者中86%最终行颅骨修补,均使用合成植入物。
- 颅骨修补后植入物取出率21%,主因为伤口裂开和感染。
- WHO 4级肿瘤及骨缺损>64.5 cm²与植入物取出风险增加相关。
核心结论
- 脑肿瘤术后因SSI去骨瓣后行颅骨修补,即使骨缺损相对较小,植入物失败风险仍较高。
- 植入物失败的预测因素有限,未测量的软组织条件等因素可能起重要作用。
- 鉴于植入物取出率高及高级别肿瘤患者生存有限,需谨慎选择患者并个体化决策。
研究设计与样本
- 多中心观察性研究,纳入2008至2022年瑞典四家神经外科中心因脑肿瘤术后SSI行去骨瓣的260例患者。
- 回顾性收集临床、影像和手术数据,采用逻辑回归和Kaplan-Meier生存分析评估植入物取出危险因素。
- 功能结局采用改良Rankin量表(mRS)评估。
主要发现
- 260例中223例(86%,中位年龄56岁)接受颅骨修补,37例(14%,中位年龄66岁)未修补,主要因预期寿命短、身体状况差或伤口问题。
- 接受颅骨修补者中最常见肿瘤为脑膜瘤(75%),中位骨缺损面积35 cm²,全部使用合成植入物。
- 总体植入物取出率为21%,主要因伤口裂开和感染。
- WHO 4级肿瘤和骨缺损>64.5 cm²与植入物取出风险增加相关(p<0.05)。
- 年龄、吸烟和糖尿病等变量未预测并发症;87%患者术后mRS不变。
临床怎么用
- 对脑肿瘤术后SSI去骨瓣患者行颅骨修补时,应告知植入物取出风险较高(21%)。
- 对WHO 4级肿瘤或骨缺损>64.5 cm²者,需个体化评估颅骨修补时机与方案。
- 高龄、吸烟、糖尿病不构成排除颅骨修补的依据,但需综合评估软组织条件。
局限性
- 回顾性观察性设计,可能存在未测量混杂因素。
- 植入物失败预测因素有限,软组织条件等未测量变量可能影响结果。
- 研究仅纳入瑞典四家中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Postoperative surgical site infections (SSIs) following brain tumor surgery frequently necessitate wound revision and bone flap removal. However, data on subsequent cranial reconstruction in this context remain limited. The aim of this study was to characterize patients undergoing bone flap removal due to SSI, determine the proportion who proceed to cranioplasty, and evaluate surgical strategies, complication rates, and risk factors for implant failure. METHODS: In this multicenter observational study, patients who underwent bone flap removal due to SSI following brain tumor surgery from 2008 to 2022 at four Swedish neurosurgical centers were included. Clinical, radiological, and surgical data were collected retrospectively. Risk factors for implant removal were evaluated with logistic regression and Kaplan-Meier survival analyses. Functional outcome was assessed using the modified Rankin Scale (mRS). RESULTS: Of 260 patients included in the analysis, 223 (86%, median age was 56 years) underwent cranioplasty and 37 (14%, median age 66 years) did not, primarily due to short life expectancy, poor medical condition, or wound concerns. Among patients who underwent cranioplasty, the most common tumor type was meningioma (75%) and the median cranial defect size was 35 cm2. Synthetic implants were used for all reconstructions. The overall implant removal rate was 21%, primarily due to wound dehiscence and infection. WHO grade 4 tumors and a cranial defect size > 64.5 cm2 were associated with an increased risk of implant removal (p < 0.05). Variables such as age, smoking, and diabetes did not predict complications. Functional outcome, as assessed by the mRS, remained unchanged postoperatively for most patients (87%). CONCLUSIONS: Cranioplasty after bone flap removal due to SSI following brain tumor surgery was associated with a substantial risk of implant failure despite reconstruction of relatively small cranial defects. Predictive factors for implant failure were limited, suggesting that unmeasured variables, such as soft tissue conditions, might play a significant role in these procedures. Given the high rate of implant removal and limited survival among patients with high-grade tumors, careful patient selection and individualized decision-making are essential.
引用
- Holmgren K, Fletcher-Sandersjöö A, Sæmundsson B, et al. Cranioplasty after surgical site infection in brain tumor patients: insights from a 15-year Swedish multicenter study. J Neurosurg. 2025. PMID: 41349038. doi:10.3171/2025.7.JNS251301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。